Dexcom hit with legal fees in AgaMatrix patent spat

 (NSDQ:DXCM) this week was ordered to pay attorney’s fees in a spat with rival AgaMatrix over patents related to continuous glucose monitoring technology.

The ruling came alongside a final judgement of non-infringement in favor of AgaMatrix from Judge S. James Otero of the US District Court for the Central District of California Western Division, according to court documents.

Read the whole story on our sister site, Drug Delivery Business

The post Dexcom hit with legal fees in AgaMatrix patent spat appeared first on MassDevice.

Patent board upholds AgaMatrix’s CGM patents in Dexcom IP spat

The legal back and forth between  (NSDQ:DXCM) and AgaMatrix over the companies’ continuous glucose monitoring IP dates back to March of 2016, when AgaMatrix launched a patent infringement lawsuit against the San Diego, Calif.-based manufacturer in the U.S. District Court of Oregon.

Later that year, Dexcom filed for inter parters review with the Patent Trial and Appeal Board, hoping that the board would find that the patents cited in AgaMatrix’s lawsuit were invalid under patent law. But today, the PTAB ruled that AgaMatrix’s patents are valid and that Dexcom failed to prove that the claims were unpatentable due to obviousness.

Get the full story at our sister site, Drug Delivery Business News.

The post Patent board upholds AgaMatrix’s CGM patents in Dexcom IP spat appeared first on MassDevice.